您的位置: 专家智库 > >

国家自然科学基金(31171243)

作品数:5 被引量:31H指数:2
相关作者:任国胜欧阳祖彬孔令泉罗鑫荣黄剑波更多>>
相关机构:重庆医科大学附属第一医院更多>>
发文基金:国家自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 5篇中文期刊文章

领域

  • 5篇医药卫生

主题

  • 3篇乳腺
  • 2篇乳腺癌
  • 2篇腺癌
  • 2篇化疗
  • 2篇PROGRE...
  • 2篇RISK_F...
  • 2篇BRCA1/...
  • 2篇BREAST...
  • 2篇DEVELO...
  • 2篇GENOMI...
  • 2篇成像
  • 1篇新辅助化疗
  • 1篇指数化
  • 1篇乳腺癌细胞
  • 1篇乳腺癌新辅助...
  • 1篇年龄
  • 1篇细胞
  • 1篇腺癌细胞
  • 1篇腺体
  • 1篇疗效

机构

  • 3篇重庆医科大学...

作者

  • 3篇任国胜
  • 2篇欧阳祖彬
  • 1篇向廷秀
  • 1篇黄剑波
  • 1篇欧阳羽
  • 1篇罗鑫荣
  • 1篇孔令泉
  • 1篇石军
  • 1篇刘潇

传媒

  • 2篇Genes ...
  • 1篇广东医学
  • 1篇第三军医大学...
  • 1篇中华内分泌外...

年份

  • 2篇2018
  • 1篇2015
  • 1篇2013
  • 1篇2012
5 条 记 录,以下是 1-5
排序方式:
Breast cancer development and progression:Risk factors,cancer stem cells,signaling pathways,genomics,and molecular pathogenesis被引量:24
2018年
As the most commonly occurring cancer in women worldwide,breast cancer poses a formidable public health challenge on a global scale.Breast cancer consists of a group of biologically and molecularly heterogeneous diseases originated from the breast.While the risk factors associated with this cancer varies with respect to other cancers,genetic predisposition,most notably mutations in BRCA1 or BRCA2 gene,is an important causative factor for this malignancy.Breast cancers can begin in different areas of the breast,such as the ducts,the lobules,or the tissue in between.Within the large group of diverse breast carcinomas,there are various denoted types of breast cancer based on their invasiveness relative to the primary tumor sites.It is important to distinguish between the various subtypes because they have different prognoses and treatment implications.As there are remarkable parallels between normal development and breast cancer progression at the molecular level,it has been postulated that breast cancer may be derived from mammary cancer stem cells.Normal breast development and mammary stem cells are regulated by several signaling pathways,such as estrogen receptors(ERs),HER2,and Wnt/b-catenin signaling pathways,which control stem cell proliferation,cell death,cell differentiation,and cell motility.Furthermore,emerging evidence indicates that epigenetic regulations and noncoding RNAs may play important roles in breast cancer development and may contribute to the heterogeneity and metastatic aspects of breast cancer,especially for triple-negative breast cancer.This review provides a comprehensive survey of the molecular,cellular and genetic aspects of breast cancer.
Yixiao FengMia SpeziaShifeng HuangChengfu YuanZongyue ZengLinghuan ZhangXiaojuan JiWei LiuBo HuangWenping LuoBo LiuYan LeiScott DuAkhila VuppalapatiHue H.LuuRex C.HaydonTong-Chuan HeGuosheng Ren
关键词:BRCA1/2
乳腺表观扩散系数与年龄及纤维腺体的关系被引量:2
2015年
目的分析不同年龄、不同乳腺纤维腺体类型与正常乳腺纤维腺体组织表观扩散系数(ADC)和指数化表观扩散系数(e ADC)的相关性。方法选择乳房MRI检查结果正常的女性228例。按年龄分为5组:A组年龄≤30岁,B组30岁<年龄≤40岁,C组40岁<年龄≤50岁,D组50岁<年龄≤60岁,E组年龄>60岁。以增强前T1WI平扫图像中的最大层面为参考,根据纤维腺体面积与乳房面积比值(R)将纤维腺体分为4种类型:Ⅰ型:致密型(R≥75%);Ⅱ型:腺体多量型(50%≤R<75%);Ⅲ型:腺体少量型(25%0.05)。不同腺体类型ADC、e ADC比较,Ⅰ型与Ⅲ、Ⅳ型比较差异有统计学意义(P<0.05);Ⅱ型与Ⅳ型比较差异有统计学意义(P<0.001);Ⅲ型与Ⅳ型比较差异有统计学意义(P<0.001)。年龄与纤维腺体类型呈正相关(r=0.487),与ADC值呈负相关(r=-0.257),与e ADC值呈正相关(r=0.238);腺体类型与ADC值呈负相关(r=-0.352),与e ADC值呈正相关(r=0.331)。结论年龄、纤维腺体类型和ADC值均匀有明显相关性,纤维腺体类型与ADC值关系更密切。纤维腺体类型变化随年龄增加具有不同步性。
欧阳祖彬鲁文力欧阳羽石军余孝勋刘潇任国胜
关键词:乳腺扩散加权成像表观扩散系数
PAQR3增强乳腺癌细胞SK-BR-3的表柔比星敏感性被引量:3
2013年
目的探讨PAQR3增强乳腺癌细胞对表柔比星的敏感性。方法采用Real-time PCR比较ER、PR及HER2受体不同的4株乳腺癌细胞(MDA-MB-231、MCF7、SK-BR-3及T47D)的PAQR3表达情况。在乳腺癌细胞SK-BR-3中转染人源性PAQR3全长表达质粒,设立对照组,观察比较转染PAQR3细胞组与空载质粒细胞组对表柔比星的敏感性,分别计算其所对应的IC50。通过细胞凋亡检测、Western blot探讨PAQR3增加表柔比星敏感性的机制。结果在4株乳腺癌细胞中,受体三阴性细胞MDA-MB-231的PAQR3表达量最高,SK-BR-3与MCF7表达量相对较低;SK-BR-3过表达PAQR3后,其对表柔比星的化疗敏感性显著升高,IC50显著降低[(25.33±0.94)μg/mL vs(17.72±1.11)μg/mL,P<0.05];PAQR3本身并未促使SK-BR-3凋亡,实验组与对照组的凋亡率差异并无统计学意义(P>0.05)。但在同等浓度表柔比星的作用下,PAQR3促使SK-BR-3表达凋亡相关蛋白Cleaved Caspase-7,从而导致表柔比星抑制率增加,对CleavedCaspase-3、Bcl-2、Bcl-xL表达则无影响。进一步分析发现,PAQR3可抑制乳腺癌化疗中表柔比星所致的ERK活化,因而促使乳腺癌细胞对表柔比星敏感。结论 PAQR3可提高乳腺癌细胞对表柔比星的化疗敏感性,PAQR3表达可能与乳腺癌对表柔比星的敏感性相关。
黄剑波罗鑫荣孔令泉向廷秀任国胜
关键词:乳腺癌表柔比星RASRAFERK化疗敏感性
磁共振成像对乳腺癌新辅助化疗疗效评价被引量:2
2012年
近年来新辅助化疗(neoadjuvantchemotherapy,NAC)已成为局部进展期乳腺癌(locallyadvancedbreastcancer,LABC)的标准治疗方法之一。但部分患者在治疗初始阶段,对治疗无反应或反应缓慢,需继续化疗才能判断疗效。如何准确有效监测NAC早期反应、预测疗效、鉴别治疗无反应者,以免遭受无效治疗、毒副反应和术后化疗盲目用药,为制定个体化治疗方案提供可靠依据极为重要。
欧阳祖彬任国胜
关键词:新辅助化疗疗效评价乳腺癌磁共振成像个体化治疗方案局部进展期
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
2018年
As the most commonly occurring cancer in women worldwide,breast cancer poses a formidable public health challenge on a global scale.Breast cancer consists of a group of biologically and molecularly heterogeneous diseases originated from the breast.While the risk factors associated with this cancer varies with respect to other cancers,genetic predisposition,most notably mutations in BRCA1 or BRCA2 gene,is an important causative factor for this malignancy.Breast cancers can begin in different areas of the breast,such as the ducts,the lobules,or the tissue in between.Within the large group of diverse breast carcinomas,there are various denoted types of breast cancer based on their invasiveness relative to the primary tumor sites.It is important to distinguish between the various subtypes because they have different prognoses and treatment implications.As there are remarkable parallels between normal development and breast cancer progression at the molecular level,it has been postulated that breast cancer may be derived from mammary cancer stem cells.Normal breast development and mammary stem cells are regulated by several signaling pathways,such as estrogen receptors(ERs),HER2,and Wnt/b-catenin signaling pathways,which control stem cell proliferation,cell death,cell differentiation,and cell motility.Furthermore,emerging evidence indicates that epigenetic regulations and noncoding RNAs may play important roles in breast cancer development and may contribute to the heterogeneity and metastatic aspects of breast cancer,especially for triple-negative breast cancer.This review provides a comprehensive survey of the molecular,cellular and genetic aspects of breast cancer.
Yixiao FengMia SpeziaShifeng HuangChengfu YuanZongyue ZengLinghuan ZhangXiaojuan JiWei LiuBo HuangWenping LuoBo LiuYan LeiScott DuAkhila VuppalapatiHue H.LuuRex C.HaydonTong-Chuan HeGuosheng Ren
关键词:BRCA1/2
共1页<1>
聚类工具0